Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma

Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iason Psilopatis, Alexandros Pergaris, Constantinos Giaginis, Stamatios Theocharis
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/31562f8e58064522ad9bb95f1f581b82
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31562f8e58064522ad9bb95f1f581b82
record_format	dspace
spelling	oai:doaj.org-article:31562f8e58064522ad9bb95f1f581b822021-11-22T01:11:22ZHistone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma1875-863010.1155/2021/7850688https://doaj.org/article/31562f8e58064522ad9bb95f1f581b822021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/7850688https://doaj.org/toc/1875-8630Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone acetylation in many cell types, thereby inducing cell cycle arrest, differentiation, and apoptotic cell death. This review is aimed at determining the role of histone acetylation and examining the therapeutic potential of histone deacetylase inhibitors in endometrial cancer. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The search terms histone deacetylase, histone deacetylase inhibitor, and endometrial cancer were employed, and we were able to identify fifty-two studies focused on endometrial carcinoma and published between 2001 and 2021. Deregulation of histone acetylation is involved in the tumorigenesis of both endometrial carcinoma histological types and accounts for high-grade, aggressive carcinomas with worse prognosis and decreased overall survival. Histone deacetylase inhibitors inhibit tumor growth, enhance the transcription of silenced physiologic genes, and induce cell cycle arrest and apoptosis in endometrial carcinoma cells both in vitro and in vivo. The combination of histone deacetylase inhibitors with traditional chemotherapeutic agents shows synergistic cytotoxic effects in endometrial carcinoma cells. Histone acetylation plays an important role in endometrial carcinoma development and progression. Histone deacetylase inhibitors show potent antitumor effects in various endometrial cancer cell lines as well as tumor xenograft models. Additional clinical trials are however needed to verify the clinical utility and safety of these promising therapeutic agents in the treatment of patients with endometrial cancer.Iason PsilopatisAlexandros PergarisConstantinos GiaginisStamatios TheocharisHindawi LimitedarticleMedicine (General)R5-920ENDisease Markers, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Iason Psilopatis Alexandros Pergaris Constantinos Giaginis Stamatios Theocharis Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
description	Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone acetylation in many cell types, thereby inducing cell cycle arrest, differentiation, and apoptotic cell death. This review is aimed at determining the role of histone acetylation and examining the therapeutic potential of histone deacetylase inhibitors in endometrial cancer. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The search terms histone deacetylase, histone deacetylase inhibitor, and endometrial cancer were employed, and we were able to identify fifty-two studies focused on endometrial carcinoma and published between 2001 and 2021. Deregulation of histone acetylation is involved in the tumorigenesis of both endometrial carcinoma histological types and accounts for high-grade, aggressive carcinomas with worse prognosis and decreased overall survival. Histone deacetylase inhibitors inhibit tumor growth, enhance the transcription of silenced physiologic genes, and induce cell cycle arrest and apoptosis in endometrial carcinoma cells both in vitro and in vivo. The combination of histone deacetylase inhibitors with traditional chemotherapeutic agents shows synergistic cytotoxic effects in endometrial carcinoma cells. Histone acetylation plays an important role in endometrial carcinoma development and progression. Histone deacetylase inhibitors show potent antitumor effects in various endometrial cancer cell lines as well as tumor xenograft models. Additional clinical trials are however needed to verify the clinical utility and safety of these promising therapeutic agents in the treatment of patients with endometrial cancer.
format	article
author	Iason Psilopatis Alexandros Pergaris Constantinos Giaginis Stamatios Theocharis
author_facet	Iason Psilopatis Alexandros Pergaris Constantinos Giaginis Stamatios Theocharis
author_sort	Iason Psilopatis
title	Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_short	Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_full	Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_fullStr	Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_full_unstemmed	Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
title_sort	histone deacetylase inhibitors: a promising therapeutic alternative for endometrial carcinoma
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/31562f8e58064522ad9bb95f1f581b82
work_keys_str_mv	AT iasonpsilopatis histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma AT alexandrospergaris histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma AT constantinosgiaginis histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma AT stamatiostheocharis histonedeacetylaseinhibitorsapromisingtherapeuticalternativeforendometrialcarcinoma
_version_	1718418272648429568

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma

Ejemplares similares